In 2020, Pyrogen Testing market for antibody contract manufacturing is expected to be worth $3.87 billion. A robust biologics pipeline and the development and marketing of next-generation biotherapeutics to treat serious life-threatening ailments like chronic illnesses, autoimmune diseases, and cancer will increase demand for contract development and manufacture.
The evolution of the illness, product approvals on a global scale, the rise in R&D partnerships between different public and private organizations, and other important factors are also projected to drive demand for antibodies contract manufacturing over the projection period.
Pyrogen testing is a critical process in the pharmaceutical industry, as it is used to determine the presence of fever-causing substances in drugs and medical devices. Pyrogens are substances that can cause fever in humans, and their presence in pharmaceutical products can have serious health consequences. The pyrogen testing market is growing due to the increasing demand for safe and effective pharmaceutical products.
The pyrogen testing market can be segmented based on product type into kits and reagents, instruments, and services. The kits and reagents segment held the largest share of the market in 2021, due to the increasing demand for pyrogen testing kits and reagents for the detection of pyrogens in pharmaceutical products.
The pyrogen testing market can also be segmented based on test type into LAL (Limulus Amebocyte Lysate) tests, in vitro tests, and rabbit tests. The LAL test segment held the largest share of the market in 2021, due to its high sensitivity and accuracy in detecting pyrogens in pharmaceutical products.
The pyrogen testing market can be segmented based on end-users into pharmaceutical and biotechnology companies, medical device companies, and other end-users. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2021, due to the increasing demand for pyrogen testing in drug development and manufacturing processes.
The pyrogen testing market can be segmented based on geography into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the market in 2021, due to the presence of a large number of pharmaceutical and biotechnology companies in the region and the increasing number of drug approvals.
Some of the key players operating in the pyrogen testing market include Associates of Cape Cod, Inc., Charles River Laboratories, Inc., Lonza Group Ltd., Merck KGaA, Thermo Fisher Scientific, Inc., Wako Chemicals USA, Inc., and others. These companies are focusing on product launches, collaborations, and partnerships to expand their product portfolio and strengthen their position in the market.
The pyrogen testing market is expected to grow significantly during the forecast period, driven by the increasing demand for safe and effective pharmaceutical products. The growing emphasis on quality control in the pharmaceutical industry and the increasing number of drug approvals are also expected to contribute to the growth of the market. The LAL test segment and the pharmaceutical and biotechnology companies segment are expected to hold the largest shares of the market.